Researchers at Baylor College of Medicine and Texas Children’s Cancer Center were awarded more than $7.6 million over four years from NCI to comprehensively study late effects of childhood cancer in a diverse population of childhood cancer survivors, including their medical, neurocognitive, and psychosocial outcomes. In addition, they will evaluate potential educational and sociodemographic barriers to obtaining survivorship care.
Gracell Biotechnologies Inc. has entered into a purchase agreement with a group of institutional and accredited healthcare specialist investors. Gracell will receive $100 million in proceeds from the private placement of ordinary shares, with up to an additional $50 million.
The DeGregorio Family Foundation with the support of the Price Family Foundation and the Esophageal Cancer Awareness Association has awarded $87,500 to Dawit Kidane-Mulat, associate professor at Howard University College of Medicine, to complete his grant focused on improving the effectiveness of immunotherapy in gastric cancers.
Krystal P. Cascetta, a 40-year-old New York City oncologist, and her 4-month-old infant daughter were found dead at a home in Somers, NY, Aug. 5 in what police describe as a possible murder-suicide.
The application period for the DKMS John Hansen Research Grant 2024 began Aug. 1.
City of Hope researchers published preclinical research in Nature Communications demonstrating that a CAR-engineered T-cell therapy worked against ovarian cancer in the laboratory and in preclinical models.
Depression and anxiety are thought to increase a person’s risk of developing cancer, but research results have been inconclusive. In an analysis of multiple studies from the Netherlands, the United Kingdom, Norway, and Canada, investigators found that depression and anxiety are not linked to higher risks for most types of cancer among this population. The analysis is published in Cancer.
Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.
Loss of a gene known as SYNCRIP in prostate cancer tumors unleashes cellular machinery that creates random mutations throughout the genome that drive resistance to targeted treatments, a team led by UT Southwestern Medical Center researchers discovered. The findings, published in Cancer Cell, could lead to interventions that thwart this process in prostate and other cancer types, making them far easier to treat.
Epstein-Barr virus infection is known to convert resting B lymphocytes into immortal cells that continuously multiply, which leads to posttransplant lymphoproliferative disorder and can evolve to lymphoma and other lymphoproliferative disorders. In a recent study, Japanese researchers discovered the molecular mechanisms of this growth transformation, demonstrating the Epstein-Barr virus induces nucleolar enlargement and increased proliferation in B cells by activating the cancer-related gene IMPDH2.
